Pre-market · Oct 8, 8:50 am ET · After hours $10.96 +1.76%
Open$10.81
Prev close$10.95
Day range$10.71 – $11.29
Volume1.40M
Market cap$916.60M
P/E (TTM)–
Dividend yield–
MLTX Stock News
Headlines matching MoonLake Immunotherapeutics or the MLTX ticker, most recent first.
H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Raises Target Price to $50PositiveMarket news · 13 Aug 2026 · Direct mention
A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $30 to $34Market news · 11 Aug 2026 · Direct mention
H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $45Market news · 20 Jul 2026 · Direct mention
Analysts Offer Insights on Healthcare Companies: Artiva Biotherapeutics, Inc. (ARTV), MoonLake Immunotherapeutics (MLTX) and MBX Biosciences, Inc. (MBX)TipRanks · 9 Jun 2026 · Direct mention
Needham Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $30Market news · 9 Jun 2026 · Direct mention
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Hinge Health, Inc. Class A (HNGE) and MoonLake Immunotherapeutics (MLTX)TipRanks · 8 Jun 2026 · Direct mention
A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $30 to $70Market news · 23 Jun 2026 · Direct mention
A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $12 to $45Market news · 12 May 2026 · Direct mention
A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $12 to $70Market news · 11 May 2026 · Direct mention
BTIG Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $30Market news · 8 Apr 2026 · Direct mention
H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $40Market news · 15 Apr 2026 · Direct mention
Needham Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $25Market news · 14 Apr 2026 · Direct mention
Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Neumora Therapeutics, Inc. (NMRA) and Aurinia Pharmaceuticals (AUPH)TipRanks · 31 Mar 2026 · Direct mention
Wolfe Research Upgrades MoonLake Immunotherapeutics(MLTX.US) to Buy Rating, Announces Target Price $24PositiveMarket news · 23 Mar 2026 · Direct mention
Citi Maintains MoonLake Immunotherapeutics(MLTX.US) With Sell Rating, Maintains Target Price $6Market news · 20 Mar 2026 · Direct mention
Discussion
No comments yet — be the first to weigh in on MLTX.
No comments yet — be the first to weigh in on MLTX.